House Bill 483 (AS PASSED HOUSE AND SENATE)
By: Representatives Stephens of the 164th and Parrish of the 158th

A BILL TO BE ENTITLED

AN ACT

To amend Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating to
controlled substances, so as to change certain provisions relating to Schedules I, IV, and V
controlled substances; to change certain provisions relating to the definition of dangerous
drug; to provide for related matters; to provide an effective date; to repeal conflicting laws;
and for other purposes.

BE IT ENACTED BY THE GENERAL ASSEMBLY OF GEORGIA:

SECTION 1.
Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating to controlled
substances, is amended by revising paragraph (12) of Code Section 16-13-25, relating to
Schedule I controlled substances, by adding a new subparagraph to read as follows:
"(W) Azaindole carboxamide;"

SECTION 2.
Said chapter is further amended by revising paragraph (34) of subsection (a) of Code
Section 16-13-28, relating to Schedule IV controlled substances, as follows:
"(34) Zopiclone (including its salts, isomers, and salts of isomers)."

SECTION 3.
Said chapter is further amended by revising Code Section 16-13-29, relating to Schedule V
controlled substances, by adding a new paragraph to read as follows:
"(1.5) Epidiolex: A drug product in finished dosage formulation in its original container
that has been approved by and labeled in compliance with the U.S. Food and Drug
Administration (FDA) that contains cannabidiol (CBD) derived from cannabis and
contains no more than 0.1 percent (w/w) residual tetrahydrocannabinols;"
SECTION 4.

Said chapter is further amended by revising subsection (b) of Code Section 16-13-71, relating to definition of dangerous drug, by adding new paragraphs to read as follows:

"(30.4) Amifampridine;"
"(62.03) Apalutamide;"
"(69.101) Avatrombopag;"
"(76.3) Baloxavir marboxil;"
"(76.8) Baricitinib;"
"(97.7) Bictegravir sodium;"
"(98.6) Binimetinib;"
"(116.3) Burosumab-twza;"
"(124.1) Calaspargase pegol-mknl;"
"(154.3) Cemiplimab-rwlc;"
"(154.4) Cenegermin-bkbj;"
"(236.8) Dacomitinib;"
"(317.1) Doravirine;"
"(325.8) Duvelisib;"
"(331.051) Elagolix sodium;"
"(331.052) Elapegademase-lvrl;"
"(331.068) Emapalumab-lzsg;"
"(331.9) Encorafenib;"
"(334.9) Eravacycline;"
"(334.92) Erenumab-aooe;"
"(386.9) Fish oil triglycerides;"
"(406.93) Fostamatinib;"
"(406.94) Fremanezumab-vfrm;"
"(408.95) Galcanezumab-gnlm;"
"(414.5) Gilteritinib;"
"(415.02) Glasdegib;"
"(463.01) Ibalizumab-uiyk;"
"(474.01) Inotersen;"
"(506.85) Ivosidenib;"
"(511.55) Lanadelumab;"
"(512.69) Larotrectinib;"
"(528.4) Lofexidine hydrochloride;"
"(529.94) Lorlatinib;"
"(531.8) Lusutrombopag;"
(531.9) Lutetium Lu 177 dotatate;"  
(617.35) Migalastat;"  
(622.8) Mogamulizumab;"  
(625.2) Moxetumomab pasudotox-tdfk;"  
(663.355) Omadacycline;"  
(692.295) Patisiran;"  
(692.519) Pegvaliase-pqpz;"  
(742.05) Plazomicin;"  
(805.3) Prucalopride;"  
(832.05) Ravulizumab;"  
(836.7) Revefenacin;"  
(842.05) Rifamycin;"  
(851.15) Sarecycline;"  
(852.5) Segesterone acetate;"  
(881.01) Sodium zirconium cyclosilicate;"  
(892.5) Stiripentol;"  
(930.91) Tafenoquine;"  
(930.975) Tagraxofusp-erzs;  
(930.976) Talazoparib;"  
(931.51) Tecovirimat;"  
(943.3) Tezacaftor;"  
(966.5) Tildrakizumab;"

SECTION 5.
Said chapter is further amended by revising paragraph (333) of subsection (b) of Code Section 16-13-71, relating to definition of dangerous drug, as follows:
"(333) Epinephrine – See exceptions;" 

SECTION 6.
Said chapter is further amended by revising paragraph (509.7) of subsection (b) of Code Section 16-13-71, relating to definition of dangerous drug, as follows:
"(509.7) Lacosamide Reserved;"

SECTION 7.
Said chapter is further amended by revising paragraph (516.75) of subsection (b) of Code Section 16-13-71, relating to definition of dangerous drug, as follows:
"(516.75) Levocetirizine dihydrochloride — See exceptions;"
SECTION 8.
Said chapter is further amended by revising paragraph (703.43) of subsection (b) of Code Section 16-13-71, relating to definition of dangerous drug, as follows:

(703.43) Perampanel Reserved;

SECTION 9.
Said chapter is further amended by revising paragraph (867) of subsection (b) of Code Section 16-13-71, relating to definition of dangerous drug, as follows:

(867) Sodium chloride injection – See exceptions;

SECTION 10.
Said chapter is further amended by revising paragraph (945.5) of subsection (b) of Code Section 16-13-71, relating to definition of dangerous drug, as follows:

(945.5) Theobromine Reserved;

SECTION 11.
Said chapter is further amended by revising paragraph (976) of subsection (b) of Code Section 16-13-71, relating to definition of dangerous drug, as follows:

(976) Triamcinolone – See exceptions;

SECTION 12.
Said chapter is further amended by revising subsection (c) of Code Section 16-13-71, relating to definition of dangerous drug, by adding new paragraphs to read as follows:

(9.33) Epinephrine – when used in a device that delivers a metered spray of 0.125 mg of epinephrine or less to provide temporary relief for symptoms of mild, intermittent asthma and is a product in finished dosage formulation in its original container that has been approved by and labeled in compliance with the U.S. Food and Drug Administration (FDA);

(12.95) Levocetirizine dihydrochloride – when used in a single dose of 5 mg or less;

(25.05) Sodium chloride injection – when in quantities of 10 cc or less and used as a catheter flush solution to act by physically occupying space within a catheter and exerting pressure on the patient's circulating blood;

(27.7) Triamcinolone acetonide – when used in a nasal spray that delivers 55 mcg per spray or less.
SECTION 13.
This Act shall become effective upon its approval by the Governor or upon its becoming law without such approval.

SECTION 14.
All laws and parts of laws in conflict with this Act are repealed.